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The adaptation of erythropoietin production to oxygen
supply is determined by the abundance of hypoxia-inducible
factor (HIF), a regulation that is induced by a prolyl
hydroxylase. To identify cells that express HIF subunits
(HIF-1a and HIF-2a) and erythropoietin, we treated
Sprague–Dawley rats with the prolyl hydroxylase inhibitor
FG-4497 for 6 h to induce HIF-dependent erythropoietin
transcription. The kidneys were analyzed for colocalization of
erythropoietin mRNA with HIF-1a and/or HIF-2a protein
along with cell-specific identification markers. FG-4497
treatment strongly induced erythropoietin mRNA exclusively
in cortical interstitial fibroblasts. Accumulation of HIF-2a was
observed in these fibroblasts and in endothelial and
glomerular cells, whereas HIF-1a was induced only in tubular
epithelia. A large proportion (over 90% in the juxtamedullary
cortex) of erythropoietin-expressing cells coexpressed HIF-2a.
No colocalization of erythropoietin and HIF-1a was found.
Hence, we conclude that in the adult kidney, HIF-2a and
erythropoietin mRNA colocalize only in cortical interstitial
fibroblasts, which makes them the key cell type for renal
erythropoietin synthesis as regulated by HIF-2a.
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Erythropoietin (EPO) is the principal regulator of red blood
cell production, linking decreased tissue oxygenation to an
adequate erythropoietic response. The adult kidney accounts
for B90% of the total EPO response, indicating that its
expression is under tight, tissue-specific regulation.1 In this
study, the critical importance of hypoxia-inducible transcrip-
tion factors (HIFs) has been well established. HIFs are
heterodimeric transcriptional regulators consisting of distinct
oxygen-sensitive a-subunits (such as HIF-1a, HIF-2a, or
HIF-3a) and a common, stable b-subunit.2 The oxygen
sensitivity of HIFs depends on the action of HIF prolyl
hydroxylases (HIF-PHD), which catalyze hydroxylation of
proline residues of HIF-a when molecular oxygen is available
as a substrate.3 Hydroxylated HIF-a is recognized by the von
Hippel Lindau protein to induce proteasomal degradation.4
Under hypoxia, degradation is inhibited and HIF-a can be
transferred to the nucleus where it recruits HIF-b and the
transcriptional coactivator p300 for its activation.2 In
addition to molecular oxygen, HIF-PHD activity depends
on the availability of 2-oxoglutarate, ferrous iron, and
ascorbate as cofactors. Pharmacological interference with
any of these cofactors has been shown to impair oxygen-
dependent HIF degradation.5–7 In this study, we used the
2-oxoglutarate analog, FG-4497, to inhibit HIF-PHDs. This
compound has been shown by us and others to enhance the
nuclear abundance of HIF isoforms, to induce the expression
of HIF target genes such as EPO, and to increase its plasma
levels without apparent toxicity.8–11
Available data obtained from cell models and transgenic
mice have provided evidence for HIF-1a and HIF-2a to
contribute to the stimulation of EPO-mRNA expression at
least under certain conditions.12–17 In the adult organism,
renal EPO expression seems to be preferentially regulated by
HIF-2a and not by HIF-1a.14,17–19 Previous work has defined
the localization of EPO synthesis in a subset of cortical
interstitial fibroblasts, which are characterized by their
or ig ina l a r t i c l e http://www.kidney-international.org
& 2010 International Society of Nephrology
Received 8 January 2009; revised 12 August 2009; accepted
30 September 2009; published online 16 December 2009
Correspondence: Sebastian Bachmann, Charite´ - Universita¨tsmedizin Berlin,
Institut fu¨r Vegetative Anatomie, Philippstr. 12, Berlin 10115, Germany.
E-mail: sbachm@charite.de
312 Kidney International (2010) 77, 312–318
expression of ecto-50-nucleotidase (50NU).20–25 In agreement
with the proposed role of HIF-2a in EPO activation, we have
shown earlier that only HIF-2a was expressed in cells of the
renal cortical interstitium.8,26–28 In contrast, HIF-1a was
distributed in tubular epithelia.8,27,28 This would imply
cellular colocalization of HIF-2a and EPO upon adequate
activation; to date, however, this has not been shown. In
addition, the identity of HIF-2a-expressing cortical inter-
stitial cells remains to be defined. Therefore, we applied
FG-4497 in rats as a suitable approach to increase HIF-a
abundance and resulting EPO mRNA expression to resolve
this issue.
RESULTS
The renal distribution of EPO mRNA signal as well as that of
HIF-1a- and HIF-2a-immunoreactive signals was deter-
mined in rats treated with FG-4497 or vehicle for 6 h
(Figure 1a–d). EPO mRNA signal, as shown by in situ
hybridization, was localized to cortical interstitial cells;
positive cells were predominantly found in the cortical
labyrinth and to a lesser extent in the medullary rays;
epithelial and vascular structures were negative (Figure 1b).
Control animals did not show reproducible EPO mRNA
staining (Figure 1a). The majority of EPO-expressing cells
were located in the juxtamedullary (deep) regions of the renal
cortex (59±3 cells per mm2), whereas in the superficial
cortex, their distribution was more scarce (25±6 cells per
mm2; Table 1). HIF immunoreactivity was principally
restricted to the cell nuclei. Staining for HIF-1a was localized
to epithelial cells, whereas nonepithelial cells were negative
(Figure 1c); signals were more frequent in the superficial
cortex (952±5 cells per mm2) than in the deep cortex
(642±7 cells per mm2; Table 1). Cortical HIF-2a staining in
the kidneys of FG-4497-treated rats was localized to
interstitial cells and to a number of endothelial and
glomerular cells (Figure 1d); interstitial HIF-2a distribution
showed no major difference between deep and superficial
cortices (123±21 vs 91±12 cells per mm2; Table 1). Kidney
samples obtained from control rats were devoid of HIF-a
signals (Table 1). Colocalization of EPO mRNA and HIF-a
isoforms was evaluated on mirror sections of the kidney
(Figure 2a–h). HIF-1a immunoreactivity did not show spatial
association with EPO mRNA expression (Figure 2a–d). By
contrast, HIF-2a immunoreactivity showed colocalization
with EPO mRNA expression in the vast majority of EPO-
producing fibroblasts in the superficial and deep regions of
the cortex (83±1.4% and 91±0.6%, respectively; Figure
2e–h; Table 1).
To identify the nature of labeled interstitial cells in FG-
4497-treated rats, we performed double staining for EPO
mRNA and the interstitial fibroblast marker, 50NU. The
resulting frequent coexpression of 50NU immunoreactive
signal and EPO mRNA within the same cells confirmed their
nature as fibroblasts, corresponding to previous evidence
obtained for this cell type under anemic and hypoxic
conditions (Figure 3).20,22,24 In contrast, caveolin-1-immuno-
reactive endothelial cells did not display EPO mRNA signal
throughout (Figure 4). To characterize HIF-2a-expressing
interstitial cells, we performed double labeling for HIF-2a
and markers for the cellular constituents of the cortical
interstitium. Strong HIF-2a immunoreactivity was found in
the nuclei of cells that also expressed the fibroblast marker
50NU (Figure 5a–c). We further observed HIF-2a staining in a
subset of nuclei of RECA-1 (rat endothelial cell antigen-1)-
positive endothelial cells (Figure 5d–f). Quantitative assess-
ment of interstitial HIF-2a distribution showed that
74±9.7% of the HIF-2a-immunoreactive nuclei belonged
to interstitial fibroblasts and 25±5.6% of them to endothelial
cells (Table 2). Major histocompatibility complex II-immuno-
reactive dendritic cells and macrophages did not show
HIF-2a immunostaining (Figure 5g–i; Table 2).
Figure 1 | Induction of renal EPO, HIF-1a, and HIF-2a signals
by FG-4497. (a) Control and (b–d) FG-4497 (FG)-treated tissues
are shown. (a) No EPO mRNA signal is detectable in control. (Panel
b) EPO mRNA in situ hybridization shows intense staining of
cortical interstitial cells in FG-treated tissues. Signal density is
highest in the juxtamedullary portion (arrowheads on the right
side of the vertical bar indicate positive cells). (c) Immunostaining
for HIF-1a shows nuclear staining of cortical tubular cells. The
density of HIF-1a-expressing cells is highest in the superficial half
of the renal cortex and decreases toward the cortico-medullary
transition. Cortical interstitial cells are negative. (d) Immunostaining
for HIF-2a shows nuclear staining of cortical interstitial cells
(arrowheads on the right side indicate positive cells). In addition,
staining can be found in the vascular endothelium and glomerular
cells. There are no major differences between the juxtamedullary
and the subcapsular region of the renal cortex. The cortical
labyrinth is marked by dashed lines. Assembled micrographs;
original magnification  100. EPO, erythropoietin; HIF,
hypoxia-inducible factor.
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To validate our model of FG-4497-induced EPO expres-
sion, we compared renal cortical EPO mRNA abundance in
FG-4497-treated animals with that in animals subjected to
isobaric hypoxic hypoxia with a FiO2 of 0.08. Hypoxia and
FG-4497 treatments caused increases in renal cortical EPO
mRNA content in a similar range; however, increases were
more pronounced in hypoxic rats (26±4-fold of control;
Po0.05) than in FG-4497-treated rats (8.5±1-fold of
control; Po0.05) (Figure 6).
DISCUSSION
Our results, for the first time, show colocalization of EPO
mRNA and HIF-2a-immunoreactive signal in interstitial
fibroblasts of the renal cortex under the HIF-stabilizing
condition of pharmacologically induced HIF-PHD inhibi-
tion. This measure was suitable to induce EPO and HIF
cellular signals reliably and reproducibly, corresponding to
the effects of established, biologically or chemically induced
systemic hypoxia. A comparison with hypoxia showed that
the obtained increases in EPO mRNAwere in a similar range,
although more pronounced in hypoxic, than in FG-4497-
treated, rats; this shows that the applied dose of FG-4497
(50mg/kg) caused an effect comparable with hypoxia in the
mild to mid-grade range.29 Marked increases in EPO mRNA
and both HIF-a isoforms upon FG-4497 treatment were
consistent with those of previous studies using HIF-PHD
inhibitors.8–11 The distribution of EPO mRNA in FG-4497-
treated animals was similar to that observed in animals
exposed to systemic hypoxia.20–25 The cellular localization of
HIF-a isoforms corresponded to that obtained in animals
that had been subjected to hypoxia or to the nonspecific
inhibitor of HIF prolyl hydroxylation, cobaltous chlor-
ide.26–28 Our analysis of serial sections stained for EPO
mRNA and HIF-a isoforms showed that the majority of
EPO-expressing fibroblasts, which showed highest density in
the juxtamedullary portions of the cortical labyrinth, also
displayed HIF-2a staining. We could further show that HIF-2a
accumulation was also localized in a fraction of capillary
endothelial cell nuclei of the peritubular interstitium. None-
theless, EPO mRNA was principally absent in these cells,
which is in agreement with the outcome of a recent
transgenic approach.24 Furthermore, EPO and HIF-1a signals
were entirely separated, as HIF-1a signals were detected only
in tubular epithelia. This is in concordance with previous
work,8,26 and in general, earlier data on an epithelial
localization of renal EPO synthesis in the adult organism
have not received further support from more recent
approaches.24,30,31
Our findings are thus consistent with an important role of
HIF-2a in the regulation of EPO mRNA expression of the
adult kidney. The fibroblast nature of HIF-2a-stained
interstitial cells was confirmed by concomitant 50NU
immunostaining and by the absence of major histocompat-
ibility complex II staining, signifying that dendritic cells or
macrophages were not involved.32 It is important to note that
HIF-2a signals––similar to EPO signals––were only found in a
fraction of 50NU-positive fibroblasts. Furthermore, only a
subset of the HIF-2a-positive cells showed concomitant EPO
expression, which implies that the cellular accumulation of
HIF-2a per se is not sufficient to induce EPO transcription.
Therefore, it is likely that further regulatory, as yet
unidentified components must act in concert with HIF-2a
to produce the typical, restricted distribution pattern of EPO
mRNA-expressing fibroblasts. A differential regulation of
these components could also be relevant for the HIF-1a-
dependent stimulation of EPO transcription under certain
conditions.13,15,16 Candidates for these components may be
GATA transcription factors, hepatocyte nuclear factor 4,
nuclear factor kB, and various protein kinases, which have all
been shown to modulate EPO.2,24,33–35 Their involvement in
the restriction of EPO in health and disease, as well as during
development, must be resolved to advance mechanistic
insights into the renal response to hypoxia. HIF-PHD
inhibitors may serve as useful tools in this study. Our data
provide no compelling evidence that the subset of interstitial
fibroblasts coexpressing EPO mRNA and HIF-2a is a cell type
of its own; rather, available evidence favors the concept of a
highly flexible potential to synthesize EPO that is not
necessarily restricted to the innermost renal cortex.23,24,36
In conclusion, we have shown that treatment with the
HIF-PHD inhibitor FG-4497 significantly increased abun-
dances in renal HIF-a protein and EPO mRNA levels.
Table 1 | Quantification of EPO mRNA, HIF-1a, and HIF-2a signals
VE IC FG IC VE tubule FG tubule
Deep Superficial Deep Superficial Deep Superficial Deep Superficial
EPO (cells per mm2±s.e.m.) 0 0 59±2.5 25±6 0 0 0 0
HIF-1a (cells per mm2±s.e.m.) 0 0 0 0 0 0 642±7.4 952±5
HIF-2a (cells per mm2±s.e.m.) 0 0 123±21 91±12 0 0 0 0
EPO+HIF-1a (%±s.e.m.) 0 0 0 0 0 0 0 0
EPO+HIF-2a (%±s.e.m.) 0 0 91±0.6 83±1.4 0 0 0 0
HIF-2a+EPO (%±s.e.m.) 0 0 51±9.5 28±3.2 0 0 0 0
Abbreviations: EPO, erythropoietin; FG, FG-4497; HIF, hypoxia-inducible factor; IC, interstitial cell; VE, vehicle.
Quantitative evaluations of superficial and juxtamedullary (deep) regions of the cortex from VE and FG-treated rats. Signals located in ICs or tubules within deep vs. superficial
cortex were evaluated. Upper three lines: Cell counts normalized for sectional area. Lower three lines: Colocalization of EPO and HIF signal as quantified on adjacent mirror
sections. Line 5 (EPO+HIF-2a) specifies the percentage of EPO mRNA-positive cells also showing a HIF-2a signal. Line 6 (HIF-2a + EPO) refers to the percentage of HIF-2a-
immunoreactive interstitial cells also expressing EPO mRNA.
Data are means±s.e.m.; n=4 per group.
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The novel findings in our study are based on cellular
colocalization strategies and include (1) the demonstration of
HIF-2a expression in cortical interstitial fibroblasts and
endothelial cells of the kidney and (2) the documentation
that cellular EPO mRNA expression was restricted to cortical
interstitial fibroblasts and colocalized with HIF-2a, but not
with HIF-1a. These findings supplement functional studies
demonstrating a prominent role of HIF-2a in the regulation
of renal EPO expression. Our data will further be relevant for
clinical trials testing HIF-stabilizing agents for the therapeu-
tic modulation of EPO.
MATERIALS AND METHODS
General
The HIF-PHD inhibitor FG-4497 was provided by FibroGen
(San Francisco, CA, USA) and used as described previously.8 Briefly,
FG-4497 was dissolved by sonification in an alkalinized 5%
glucose solution (10mg/dl; pH 8.7) and applied intravenously at a dose
of 50mg/kg body weight. This dose has been previously shown to be
well tolerated and to markedly increase plasma EPO levels
in mice and Rhesus Macaques within 4–6 h.8–11
Animal models and tissue preparation
Animal studies were conducted in accordance with the German law
for animal protection (reference nos G0014/07 and G0189/07 of the
Berlin Senate) and NIH policies. Adult male Sprague–Dawley rats
(body weight 250 g) were used throughout the study. FG-4497 or
vehicle was applied intravenously after anesthesia with isoflurane
(inhalation) or intraperitoneal injection of ketamine (100mg/kg
intraperitoneally). Rats were subsequently allowed to regain
consciousness for the treatment period of 6 h. After treatment,
Figure 2 | EPO mRNA colocalizes with HIF-2a but not with
HIF-1a. (a,c,e,g) Comparative localization of EPO mRNA,
(b,d) HIF-1a immunoreactivity, and (f,h) HIF-2a immunoreactivity
on consecutive (mirror) sections of FG-4497-treated tissues;
images are arranged pairwise. (a–d) EPO in situ signals and HIF-1a
immunoreactivity are not coexpressed as shown in the overview
(a and b) and detail (c and d; boxed in overviews). In contrast, EPO
in situ signals and HIF-2a immunoreactivity are frequently
coexpressed in cortical interstitial fibroblasts as shown by the
overview (e and f) and detail (g and h; boxed in overviews).
Circumferences of EPO-expressing fibroblasts are marked for
clarity and numbered (I–V) in panels g and h. Original
magnification  400. EPO, erythropoietin; HIF, hypoxia-inducible
factor.
Figure 3 | EPO mRNA colocalizes with ecto-50-nucleotidase.
(a) Representative localization of EPO mRNA and (b) the fibroblast
marker, ecto-50-nucleotidase (50NU); double staining on the same
section from FG-4497-treated tissues. All EPO-expressing cells are
located in the cortical interstitium and also stain positive for 50NU.
Boxes in panels a and b highlight the typical staining pattern.
Original magnification  400. EPO, erythropoietin.
V V
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Figure 4 | EPO mRNA does not colocalize with caveolin-1.
(a) Comparative localization of EPO mRNA and (b) the endothelial
marker, caveolin (Cav)-1; double staining on the same section
from FG-4497-treated tissues. EPO mRNA and Cav-1 show
complete separation of signals, indicating that EPO is not
expressed in endothelial cells. Cell circumferences are marked for
clarity. Arrows point to an endothelial cell. V, vein. Original
magnification  400. EPO, erythropoietin.
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the kidneys were either perfusion-fixed with 3% paraformaldehyde
through the abdominal aorta (n¼ 4 per group)20 or processed for
mRNA isolation (n¼ 5 per group). In a parallel approach, rats were
subjected to isobaric hypoxic hypoxia in a sealed hypoxic chamber
(FiO2 0.08; 6 h; n¼ 5 per group), anesthetized after the treatment
period, killed, and the kidneys were harvested for mRNA isolation.
The renal cortex was separated from the medulla at 30 1C using a
sterile razor blade. Tissue samples were processed for mRNA
isolation using the Qiagen RNeasy kit (Qiagen, Hilden, Germany).
cDNA was prepared using the Bioline cDNA synthesis kit (Bioline,
London, UK). Renal EPO mRNA content was determined in FG-
4497- and hypoxia-treated animals by Taqman real-time PCR using
an Applied Biosystems 7500 Fast Real-Time PCR system and the
murine EPO probe Mm_01202755 (Applied Biosystems, Darmstadt,
Germany). Glyceraldehyde-3-phosphate dehydrogenase content was
determined simultaneously and served as a loading control.
For localization studies, renal EPO mRNA expression was
detected by nonradioactive mRNA in situ hybridization, with a
probe covering base pairs 312–602 of rat EPO cDNA
(NM_0171001). HIF-a immunostaining was performed using
established antisera and a high-amplification technique.8,12,27
a b c
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Figure 5 |HIF-2a immunoreactivity colocalizes with ecto-50-nucleotidase and RECA-1, but not with MHC II. (a,d,g) Comparative
localization of HIF-2a and (b) 50NU, (e) the endothelial marker RECA-1, and (h) MHC II; double staining on the same sections from FG-4497-
treated tissues. In the merged color images (c,f,i), green signals mark HIF-2a and red signals indicate 50NU (c), RECA-1 (f), and MHC II
(i). The majority of HIF-2a-immunoreactive cortical interstitial cells also stain positive for 50NU (arrowheads). Inserts show high-power
magnifications of a HIF-2a-positive interstitial fibroblast (c) and a HIF-2a-immunoreactive endothelial cell (f). Arrowheads indicate
coexpression of HIF-2a and the respective marker, arrows point to HIF-2a-positive cells not expressing the respective marker, and bars
indicate cells expressing the respective marker, but not HIF-2a. Original magnification  400. HIF-2a, hypoxia-inducible factor-2a; MHC II,
major histocompatibility complex II; 50NU, ecto-50-nucleotidase; RECA-1, rat endothelial cell antigen-1.
Table 2 | Numerical evaluation of HIF-2a- and specific
marker-labeled cells
Interstitial cells
(per  400 field)
HIF-2a pos.
(per  400 field)
HIF-2a and
marker (%)
RECA-1 18±3.3 6.5±1.5 25±5.6
Ecto-5’-nucleotidase 17±1.35 6.9±0.7 74±9.7
MHC II 17±1.74 6.6±1.5 0
Abbreviations: DAPI, 40-6-diaminidine-2-phenyl indole; HIF-2a, hypoxia-inducible
factor-2a; MHC II, major histocompatibility complex II; pos., positive; RECA-1, rat
endothelial cell antigen-1.
Cells were counted per optical field as viewed on double-stained sections from FG-
4497-treated tissues. Categories refer to the absolute number of interstitial cells
identified by DAPI nuclear stain, number of HIF-2a-positive cells, and percentage of
the HIF-2a-positive cells that co-express one of the markers listed. Data are
means±s.e.m.
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Colocalization of EPO mRNA and HIF-2a protein was studied on
consecutive 3-mm-thick paraffin sections; these were analyzed at
their mirror surfaces and the images reoriented electronically. Cell
counting was performed in the deep vs superficial halves of the
cortex on sections stained for the respective HIF-a isoforms and
EPO mRNA. Sections were examined using a Leica DMRB
microscope equipped with an interference contrast module (Leica,
Wetzlar, Germany). Images were acquired using a SPOT RT 2.3.0
digital camera (Diagnostic Instruments, Sterling Heights, MI, USA)
and the MetaVue imaging System (Molecular Devices, Downing-
town, PA, USA). To optimize the resolution of overview micro-
graphs, two adjacent  100 pictures of each staining were acquired
and subsequently aligned electronically.
Characterization of EPO-expressing cortical interstitial cells was
performed by double labeling EPO mRNA-stained sections with
antibodies against 50NU (rabbit anti-CD73; kind gift from Michel
LeHir, Zurich, Switzerland) for interstitial fibroblasts,20,32 and
caveolin-1 (Santa Cruz Antibodies, Santa Cruz, CA, USA) for
endothelial cells.37 HIF-2a-immunoreactive cortical interstitial cells
were characterized by double-staining procedures using mouse
monoclonal anti-50NU (BD Pharmingen, Heidelberg, Germany),38
the endothelial cell marker RECA-1 (ABD Serotec, Oxford, UK),39
or the dendritic cell marker major histocompatibility complex II
(Harlan Sera-lab, Belton, UK).32 For double labeling, 6-mm-thick
cryostat sections were first stained for RECA-1, 50NU, or major
histocompatibility complex II according to standard protocols.
Bound antibody was detected using a Cy3-labeled donkey anti-
mouse secondary antibody (Dianova, Hamburg, Germany). After
completion of the first staining procedure, sections were postfixed
for 10min using 3% paraformaldehyde in phosphate-buffered
saline. The sections were subsequently subjected to HIF-2a
immunostaining using the high-amplification technique.27 Cy2-
conjugated streptavidin (Dianova) was used for detection. Nuclei
were stained with DAPI (40-6-diaminidine-2-phenyl indole; Sigma,
Sigma-Aldrich, Munich, Germany). Sections were analyzed under a
LSM5 Exciter confocal microscope (Zeiss, Jena, Germany). To
quantify the extent of colocalization of HIF-2a with the different
markers, 10 micrographs of the cortical interstitium, taken at
random from FG-4497-treated rats (n¼ 4), were analyzed (magni-
fication  400).
Analysis of data
Results were evaluated using routine parametric descriptive
statistics. Groups were compared with the unpaired t-test. A
probability level of Po0.05 was accepted as significant. Values are
given as means±s.e.m.
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